Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia

Critical Care Medicine

Volumn 36, Issue 8, 2008, Pages 2388-2394

  Lasocki, Sigismond ^a,b   Millot, Sarah ^a   Andrieu, Valérie ^b   Lettéron, Philippe ^a   Pilard, Nathalie ^a   Muzeau, Françoise ^a   Thibaudeau, Olivier ^b   Montravers, Philippe ^b   Beaumont, Carole ^a  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Anemia; Erythropoietin; Ferroportin; Hepcidin; Intensive care; Iron

Indexed keywords

DIAMINOBENZIDINE; ERYTHROPOIETIN; FERRITIN; FERROPORTIN; HEPCIDIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; NONHEME IRON PROTEIN; ZYMOSAN; ANTIMICROBIAL CATIONIC PEPTIDE; CATION TRANSPORT PROTEIN; IRON; METAL TRANSPORTING PROTEIN 1;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; ERYTHROPOIESIS; IMMUNOCYTOCHEMISTRY; INTENSIVE CARE ANEMIA; IRON BALANCE; IRON KINETICS; IRON STORAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; ORBIT; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PUNCTURE; SEPTIC SHOCK; SPLEEN; ANIMAL; C57BL MOUSE; CELL MEMBRANE; DRUG EFFECT; GENETICS; HOMEOSTASIS; LIVER MICROSOME; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANEMIA; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CATION TRANSPORT PROTEINS; CELL MEMBRANE; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; HOMEOSTASIS; INTERLEUKIN-6; IRON; MALE; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; PHLEBOTOMY; RNA, MESSENGER;

EID: 49949085724     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31818103b9     Document Type: Article

References (37)

1. Vincent JL, Baron JF, Reinhart K, et al: Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507
2. Corwin HL, Gettinger A, Pearl RG, et al: The CRIT Study: Anemia and blood transfusion in the critically ill - Current clinical practice in the United States. Crit Care Med 2004; 32: 39-52
3. Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-417
4. Corwin HL, Krantz SB: Anemia of the critically ill: "Acute" anemia of chronic disease. Crit Care Med 2000; 28:3098-3099
5. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005; 352:1011-1023
6. Burnum JF: Medical vampires. N Engl J Med 1986; 314:1250-1251
7. Nguyen BV, Bota DP, Melot C, et al: Time course of hemoglobin concentrations in non-bleeding intensive care unit patients. Crit Care Med 2003; 31:406-410
8. von Ahsen N, Muller C, Serke S, et al: Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 1999; 27:2630-2639
9. Robinson Y, Hostmann A, Matenov A, et al: Erythropoiesis in multiply injured patients. J Trauma 2006; 61:1285-1291
10. Darveau M, Denault AY, Blais N, et al: Bench-to-bedside review: Iron metabolism in critically ill patients. Crit Care 2004; 8:356-362
11. Park CH, Valore EV, Waring AJ, et al: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810
12. Nicolas G, Viatte L, Bennoun M, et al: Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002; 29:327-335
13. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102:783-788
14. Ganz T: Hepcidin in iron metabolism. Curr Opin Hematol 2004; 11:251-254
15. Donovan A, Brownlie A, Zhou Y, et al: Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403:776-781
16. Nemeth E, Tuttle MS, Powelson J, et al: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internaliza-tion. Science 2004; 306:2090-2093
17. Delaby C, Pilard N, Goncalves AS, et al: The presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and downregulated by hepcidin. Blood 2005; 106:3979-3984
18. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, et al: Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000; 28:2773-2778
19. Bellamy MC, Gedney JA: Unrecognized iron deficiency in critical illness. Lancet 1998; 352:1903
20. Nicolas G, Chauvet C, Viatte L, et al: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-1044
21. Pak M, Lopez MA, Gabayan V, et al: Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006; 108: 3730-3735
22. Volman TJ, Hendriks T, Goris RJ: Zymosan-induced generalized inflammation: Experimental studies into mechanisms leading to multiple organ dysfunction syndrome. Shock 2005; 23:291-297
23. Volman TJ, Goris RJ, van der Meer JW, et al: Tissue- and time-dependent upregulation of cytokine mRNA in a murine model for the multiple organ dysfunction syndrome. Ann Surg 2004; 240:142-150
24. Viatte L, Nicolas G, Lou DQ, et al: Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. Blood 2006; 107:2952-2958
25. Nicolas G, Bennoun M, Devaux I, et al: Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98:8780-8785
26. Lam-Yuk-Tseung S, Govoni G, Forbes J, et al: Iron transport by Nramp2/DMT1: pH regulation of transport by 2 histidines in transmembrane domain 6. Blood 2003; 101: 3699-3707
27. Martin ME, Nicolas G, Hetet G, et al: Transferrin receptor 1 mRNA is downregulated in placenta of hepcidin transgenic embryos. FEBS Lett 2004; 574:187-191
28. Nemeth E, Rivera S, Gabayan V, et al: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276
29. Lee P, Peng H, Gelbart T, et al: Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 2005; 102:1906-1910
30. Kemna E, Pickkers P, Nemeth E, et al: Timecourse analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106:1864-1866
31. Vokurka M, Krijt J, Sulc K, et al: Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 2006; 55:667-674
32. Zarychanski R, Turgeon AF, McIntyre L, et al: Erythropoietin-receptor agonists in critically ill patients: A meta-analysis of randomized controlled trials. CMAJ 2007; 177:725-734
33. Corwin HL, Gettinger A, Fabian TC, et al: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357:965-976
34. Beshara S, Lundqvist H, Sundin J, et al: Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anemic patients: A study using positron emission tomography. Br J Haematol 1999; 104:296 -302
35. Henry DH, Dahl NV, Auerbach M, et al: Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12:231-242
36. Auerbach M, Ballard H, Trout JR, et al: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307
37. Hedenus M, Birgegard G, Nasman P, et al: Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 2007; 21:627-632